347 related articles for article (PubMed ID: 12523370)
21. The role of civil society in protecting public health over commercial interests: lessons from Thailand.
Ford N; Wilson D; Bunjumnong O; von Schoen Angerer T
Lancet; 2004 Feb; 363(9408):560-3. PubMed ID: 14975620
[No Abstract] [Full Text] [Related]
22. Access to life-saving medicines and intellectual property rights: an ethical assessment.
Schroeder D; Singer P
Camb Q Healthc Ethics; 2011 Apr; 20(2):279-89. PubMed ID: 21435303
[No Abstract] [Full Text] [Related]
23. HIV: the other dimension.
Adler MW
Lancet; 1997 Feb; 349(9050):498-500. PubMed ID: 9040592
[TBL] [Abstract][Full Text] [Related]
24. Compulsory licensing for bridging the gap - treatment access in developing countries: interview with James Love, Consumer Project on Technology. Interview by John S. James.
Love J
AIDS Treat News; 1999 Mar; (No 314):1-7. PubMed ID: 11366241
[TBL] [Abstract][Full Text] [Related]
25. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
26. Intellectual property rights, the World Trade Organization and public health: the Brazilian perspective.
Viana JM
Conn J Int Law; 2002; 17(2):311-8. PubMed ID: 12688298
[No Abstract] [Full Text] [Related]
27. Ethics and AIDS drugs.
Dowell W
Time; 1999 Jul; 154(2):49. PubMed ID: 10538646
[No Abstract] [Full Text] [Related]
28. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
29. Human rights and fair access to medication.
Rubenstein LS
Emory Int Law Rev; 2003; 17():525-34. PubMed ID: 15732190
[No Abstract] [Full Text] [Related]
30. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
Halliburton M
Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
[TBL] [Abstract][Full Text] [Related]
31. Cheaper AIDS drugs due for Third World.
Brown P
Nature; 2000 May; 405(6784):263. PubMed ID: 10830927
[No Abstract] [Full Text] [Related]
32. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
Resnik DB; DeVille KA
Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852
[No Abstract] [Full Text] [Related]
33. Global patent police block cost-reduction efforts.
Kasper T
GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
[TBL] [Abstract][Full Text] [Related]
34. "Rights" and wrongs: what utility for the right to health in reforming trade rules on medicines?
Forman L
Health Hum Rights; 2008; 10(2):37-52. PubMed ID: 20845858
[TBL] [Abstract][Full Text] [Related]
35. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
Effingham AM
Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613
[No Abstract] [Full Text] [Related]
36. The World Health Organization's prequalification program and its potential effect on data exclusivity laws.
Childs DW
Food Drug Law J; 2005; 60(1):79-97. PubMed ID: 15940855
[No Abstract] [Full Text] [Related]
37. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
Velasquez G
Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
[TBL] [Abstract][Full Text] [Related]
38. Access to HIV drugs: are we changing the two world paradigm?
Lazzarini Z
Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297
[No Abstract] [Full Text] [Related]
39. [Pharmaceutical patents and public health: challenges for the Brazilian antiretroviral treatment policy].
Meiners CM
Cad Saude Publica; 2008 Jul; 24(7):1467-78. PubMed ID: 18670671
[TBL] [Abstract][Full Text] [Related]
40. Africa, access, and patents: moving fast.
James JS
AIDS Treat News; 1999 Jul; (No 322):5-8. PubMed ID: 11366567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
